AI Engines For more Details: Perplexity Kagi Labs You
Topical Antibacterial Treatment: Nitrofurazone is primarily used topically to prevent and treat bacterial infections of the skin. It is effective against a wide range of bacteria, including both gram-positive and gram-negative organisms. It works by interfering with the bacterial cell wall synthesis, leading to bacterial cell death.
Burns and Wounds: Nitrofurazone is commonly used in the management of burns, including thermal burns, chemical burns, and radiation burns. It helps prevent bacterial infections in the burned area and promotes wound healing. The medication is often applied as a topical cream or ointment directly to the affected area.
Skin Infections: In addition to burns, nitrofurazone may be used to treat various skin infections, such as cuts, scrapes, abrasions, and minor surgical wounds. It helps prevent bacterial growth in the wound site and reduces the risk of secondary infections.
Pressure Ulcers: Nitrofurazone may also be employed in the treatment of pressure ulcers (bedsores). These ulcers occur due to prolonged pressure on specific areas of the body, leading to tissue damage and breakdown. Nitrofurazone can help prevent bacterial colonization in these ulcers and promote healing.
Dermatitis and Dermatosis: Nitrofurazone may be used in the management of certain dermatological conditions characterized by bacterial infections or inflammation, such as dermatitis and dermatosis. It helps alleviate symptoms and prevent further complications associated with bacterial overgrowth.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bacteroides xylanisolvens | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.9 | 0.9 | 0 |
| ADHD | 5.4 | 2 | 1.7 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.7 | 3.4 | 0.09 |
| Allergies | 9.9 | 5.8 | 0.71 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 8.8 | 8.3 | 0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.2 | 2 | 1.6 |
| Ankylosing spondylitis | 5.3 | 1.8 | 1.94 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.3 | 0.97 |
| Atherosclerosis | 2.7 | 3.3 | -0.22 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 12.7 | 11.8 | 0.08 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.8 | 0.3 | 5 |
| Cancer (General) | 0.9 | 2.9 | -2.22 |
| Carcinoma | 5.2 | 2.6 | 1 |
| Celiac Disease | 3.6 | 4.2 | -0.17 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.3 | 0.58 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3.6 | 2 | 0.8 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 4.9 | 2.5 | 0.96 |
| Colorectal Cancer | 12.2 | 4.1 | 1.98 |
| Constipation | 3 | 2.5 | 0.2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12.1 | 15.1 | -0.25 |
| Crohn's Disease | 10.3 | 6.8 | 0.51 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 4.1 | 1.4 | 1.93 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.5 | 11 | 0.23 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 3.2 | -0.39 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.4 | 2.8 | 0.57 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 3.6 | 0.03 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.6 | 1.69 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.8 | 2.9 | 0.31 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 3.1 | 1.8 | 0.72 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.5 | -1.78 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.2 | 1 |
| Heart Failure | 5.6 | 3.2 | 0.75 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2.2 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.7 | 6.8 | -0.19 |
| Hypothyroidism | 1.3 | 1 | 0.3 |
| Hypoxia | 4 | 0.9 | 3.44 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 11.9 | 12 | -0.01 |
| Insomnia | 3.4 | 3.5 | -0.03 |
| Intelligence | 2.6 | 0.6 | 3.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 10.4 | 6.3 | 0.65 |
| ischemic stroke | 3.7 | 1.7 | 1.18 |
| Liver Cirrhosis | 9.2 | 5.9 | 0.56 |
| Long COVID | 8.7 | 9.2 | -0.06 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.7 | 1 | 1.7 |
| Metabolic Syndrome | 9.4 | 9.5 | -0.01 |
| Mood Disorders | 13.4 | 9 | 0.49 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 9.6 | 7.8 | 0.23 |
| Multiple system atrophy (MSA) | 2.2 | 0.7 | 2.14 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 3.1 | -1.58 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.9 | 0.1 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 13.4 | 10.1 | 0.33 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.6 | 1.06 |
| Osteoporosis | 3.1 | 2.2 | 0.41 |
| pancreatic cancer | 2.3 | 0.6 | 2.83 |
| Parkinson's Disease | 11.2 | 10.2 | 0.1 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.3 | 4 | 0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.5 | 4.7 | 1.02 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 8.4 | 3.5 | 1.4 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.7 | 3.3 | 0.12 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 2.9 | -0.93 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 6.3 | 5 | 0.26 |
| Type 2 Diabetes | 11 | 9.5 | 0.16 |
| Ulcerative colitis | 7.6 | 10 | -0.32 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
